U.S. Markets closed
  • S&P 500

    4,145.19
    -6.75 (-0.16%)
     
  • Dow 30

    32,803.47
    +76.67 (+0.23%)
     
  • Nasdaq

    12,657.55
    -63.04 (-0.50%)
     
  • Russell 2000

    1,921.82
    +15.36 (+0.81%)
     
  • Crude Oil

    88.53
    -0.01 (-0.01%)
     
  • Gold

    1,792.40
    -14.50 (-0.80%)
     
  • Silver

    19.86
    -0.26 (-1.30%)
     
  • EUR/USD

    1.0185
    -0.0065 (-0.6315%)
     
  • 10-Yr Bond

    2.8400
    +0.1640 (+6.13%)
     
  • Vix

    21.15
    -0.29 (-1.35%)
     
  • GBP/USD

    1.2070
    -0.0088 (-0.7266%)
     
  • USD/JPY

    134.9700
    +1.9540 (+1.4690%)
     
  • BTC-USD

    23,211.14
    +20.93 (+0.09%)
     
  • CMC Crypto 200

    533.20
    -2.02 (-0.38%)
     
  • FTSE 100

    7,439.74
    -8.32 (-0.11%)
     
  • Nikkei 225

    28,175.87
    +243.67 (+0.87%)
     

Aileron Shares Fall After Early Data From Chemoprotective Agent In Lung Cancer Setting

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Aileron Therapeutics (NASDAQ: ALRNannounced interim data from its Phase 1b chemoprotection trial of patients with advanced p53-mutated non-small cell lung cancer (NSCLC) undergoing treatment with first-line carboplatin plus pemetrexed with or without immune checkpoint inhibitors.

  • ALRN-6924-treated patients could stay on chemotherapy treatment longer, completing 93% of the first four cycles of carboplatin/pemetrexed administered compared to 78% on placebo.

  • This imbalance of completed cycles may have introduced a bias against ALRN-6924 on the composite primary endpoint.

  • The imbalance increases further when looking at percentages of patients completing six cycles of treatment (79% on ALRN-6924 versus 57% on placebo).

  • This is reflected in the progression-free survival, which was 4.6 months in the ALRN-6924 arm versus 3.2 months in the placebo arm.

  • ALRN-6924-treated patients demonstrated 56% of cycles free from serious/severe hematologic toxicities and related events compared to 50% on placebo.

  • Aileron plans to stop further enrollment in the NSCLC trial and apply key learnings to strengthen the Phase 1b breast cancer trial.

  • Additionally, Aileron plans to modify the dosing strategy for the trial and will not further enroll additional patients in the ongoing 0.3 mg/kg and 0.6 mg/kg dose cohorts.

  • Price Action: ALRN shares are down 33.60% at $0.27 during the premarket session on the last check Wednesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.